Please use this identifier to cite or link to this item: https://doi.org/10.1089/ten.tea.2009.0680
DC FieldValue
dc.titleBeyond cell capture: Antibody conjugation improves hemocompatibility for vascular tissue engineering applications
dc.contributor.authorChong, M.S.K.
dc.contributor.authorTeoh, S.-H.
dc.contributor.authorTeo, E.Y.
dc.contributor.authorZhang, Z.-Y.
dc.contributor.authorLee, C.N.
dc.contributor.authorKoh, S.
dc.contributor.authorChoolani, M.
dc.contributor.authorChan, J.
dc.date.accessioned2014-06-17T06:13:39Z
dc.date.available2014-06-17T06:13:39Z
dc.date.issued2010-08-01
dc.identifier.citationChong, M.S.K., Teoh, S.-H., Teo, E.Y., Zhang, Z.-Y., Lee, C.N., Koh, S., Choolani, M., Chan, J. (2010-08-01). Beyond cell capture: Antibody conjugation improves hemocompatibility for vascular tissue engineering applications. Tissue Engineering - Part A 16 (8) : 2485-2495. ScholarBank@NUS Repository. https://doi.org/10.1089/ten.tea.2009.0680
dc.identifier.issn19373341
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/59624
dc.description.abstractAntibody-conjugated surfaces are being studied for cardiovascular implant applications to capture endothelial progenitor cells and promote endothelialization. However, despite the large amount of literature on endothelial progenitor cell capture efficiency, little effort has been made to understand acute blood responses to the modified surfaces. We hypothesize that CD34 antibody conjugation passivates surfaces against procoagulatory events, and thus improves hemocompatibility. To test this hypothesis, we subjected the modified films to hemocompatibility tests to evaluate contact activation, platelet adhesion and activation, as well as whole blood clotting response to the films. Here, we demonstrate the alteration of blood responses due to polyacrylic acid (PAAc) engraftment and subsequent antibody conjugation on biaxially stretched polycaprolactone (PCL) films. Compared to PCL, PAAc-engrafted PCL (PCL-PAAc) and CD34-antibody-conjugated films (PCL-PAAC-CD34) resulted in a four-to ninefold (p<0.001) reduced platelet activation. PCL-PAAc, however, resulted in an increased contact activation on thromboelastography, and a poorer blood compatibility index assay (43.4%±2.3% vs. 60.9%±2.5%, p<0.05). PCL-PAAC-CD34, on the other hand, resulted in delayed clot formation (r=19.3±1.5, k=6.8±0.6min) and reduced platelet adhesion and activation, and yielded the highest blood compatibility index score, indicating least thrombogenicity (69.3%±3.2%). Our results suggest that CD34 antibody conjugation significantly improved the hemocompatibility of PAAc-conjugated PCL. © 2010, Mary Ann Liebert, Inc.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1089/ten.tea.2009.0680
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentMECHANICAL ENGINEERING
dc.description.doi10.1089/ten.tea.2009.0680
dc.description.sourcetitleTissue Engineering - Part A
dc.description.volume16
dc.description.issue8
dc.description.page2485-2495
dc.identifier.isiut000280648700008
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

21
checked on Oct 15, 2019

WEB OF SCIENCETM
Citations

18
checked on Oct 15, 2019

Page view(s)

80
checked on Oct 13, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.